News and Media
News and Media
Valerio Therapeutics Reports its Half-Year 2024 Financial Results and Provides an Update on its Activities
September 30, 2024
Valerio Therapeutics Acquires Emglev Therapeutics, a Single-domain Antibody-based Therapeutics Company
September 30, 2024
Half-year liquidity contract statement for Valerio Therapeutics
September 29, 2024
Valerio Therapeutics: report on the Combined General Meeting of June 5, 2024
June 5, 2024
Valerio Therapeutics Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial
May 22, 2024
Publication of the 2023 Annual Report
April 30, 2024
Valerio Therapeutics Reports Full Year 2023 Financial Results and Provides Clinical Development Updates
April 30, 2024
Valerio Therapeutics announces a capital reduction motivated by losses by reducing the nominal value of the Company’s shares
February 5, 2024
Half-year liquidity contract statement for Valerio Therapeutics
January 25, 2024
Valerio Therapeutics Reports its Half-Year 2023 Financial Results and Provides an Update on its Activities (English)
New identity unveiled, with the aim at developing innovative therapies […]
September 28, 2023
Onxeo changes its name and becomes Valerio Therapeutics following approval by the Annual General Meeting of June 6, 2023 (English)
All the resolutions approved by the Board of Directors were […]
June 6, 2023
Combined General Meeting of June 6, 2023: availability of preparatory documents and participation & voting procedures (English)
May 16, 2023
Combined General Meeting of June 6, 2023: availability of preparatory documents and participation & voting procedures
May 16, 2023
Publication of the 2022 Annual Financial Report
April 28, 2023
Onxeo Reports Full Year 2022 Financial Results and Provides Clinical Development Updates
April 24, 2023
Press Release Signup
Subscribe to receive our Press Releases when they come out.
